Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATETM study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

ConclusionIbrutinib led to significant improvements in hematologic function and disease symptomatology vs ofatumumab, and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research